Abnova, founded in Year 2002 and held its Initial Public Offering (IPO) in Taiwan in Year 2009, is the first biotech company success-fully integrated the IT-style management and industrial-scale antibody manufacturing. It is also the world's largest antibody manufacturer. Rather than the traditional method of antibody production, Abnova is taking a genomic/proteomic approach for the antibody development. Our goal is to have at least one antibody to every human expressed gene in human genome. In Phase I of our business plans, we vastly expand the scope and availability of antibody reagents for the research market by taking a genome-wide approach to the high throughput production of human protein and antibody. We manufacture all our products, including recombinant proteins and antibodies, in our state-of-the-art production and SPF animal facilities. These products are marketed through a combination of E-commerce based direct sales and a multi-tiered, sales network of over 49 distributors. We are dedicated to providing our clients from the academic institutions or industry the highest quality products and biomedical reagents to accelerating life science research and development. Leveraging on a solid foundation of antibody manufacturing, expanding antibody bank, and increasing customer base, Abnova continues to grow its business and products worldwide, at the same time establishing an unprecedented, global network of collaborators contributing to the next generation's product ideas and developments. Starting from Year 2009 to 2013, in Phase II of our business plans, we have diversified into the systems arena focusing on antibody pairs, ELISA kits and instrumentations for rare cell isolation. In Phase III (Year 2014 to 2016), we focus on in vitro diagnostics development concentrating on non-invasive, liquid biopsies of circulating tumor cells, ctDNA, and exosomes for precision medicine. In the future, phase IV (Year 2017 and later), we will focus on drug development specializing on immunotherapy. The value-added business has set the path of company's future growth and provided an opportunity for Abnova to contribute to the biotech industry at large.

亞諾法生技股份有限公司創立於2002年，並於2009年在臺灣證券交易所公開上市，是臺灣第一家成功整合IT式管理與工業規模生產的生物技術公司，也是全球最大的抗體製造商。不同于傳統的抗體製造方式，亞諾法採用染色體組/蛋白質組的創新模式進行抗體開發與生產。公司成立之初便以“一個基因，一個抗體”為使命，讓人類的每個基因，至少都有一個對應的抗體可以使用。基於創新生產模式和最先進的技術及無特定病源(SPF)的動物與設施，大量且快速地生產人類的各種蛋白與抗體，並以直銷的電子商務模式和超過49個經銷商的多層次營銷網絡將產品銷往全球，滿足了全世界範圍內研究市場多樣化的抗體試劑需求。亞諾法致力於為學術研究單位或生技產業提供最高品質的產品，以期成為生命科學研究發展的關鍵推動者。 憑藉成熟的抗體開發生產基礎、規模持續擴大的抗體庫、以及日益增加的專業客戶群，亞諾法持續深化拓展業務，產品暢銷世界各地，同時建立了前所未有的全球合作網絡。2009年至2013年是公司發展的第二階段，著重於多樣化系統性產品開發，包含抗體配對、ELISA試劑盒與CTC循環罕見細胞分離的儀器等。在運營發展邁入第三階段 (2014年至 2016年)，為了用於精準醫療我們專注於發展體外檢測循環腫瘤細胞、循環腫瘤DNA與外泌體等非侵入性液體活檢的檢測技術。而在邁入未來第四階段之際 (2017年~)，亞諾法將提升發展層次，著眼於治療用途的單克隆抗體藥物開發，推動下一代產品的開發與應用。這些高價值業務必將為亞諾法提供更加廣闊的發展前景，同時為生物與醫療產業的發展做出更大的貢獻。